384 related articles for article (PubMed ID: 22669255)
21. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
[TBL] [Abstract][Full Text] [Related]
22. Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.
Wulfert S; Kratochwil C; Choyke PL; Afshar-Oromieh A; Mier W; Kauczor HU; Schenk JP; Haberkorn U; Giesel FL
Mol Imaging Biol; 2014 Aug; 16(4):586-94. PubMed ID: 24526358
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
24. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia.
Froeling V; Elgeti F; Maurer MH; Scheurig-Muenkler C; Beck A; Kroencke TJ; Pape UF; Hamm B; Brenner W; Schreiter NF
Ann Nucl Med; 2012 Nov; 26(9):738-43. PubMed ID: 22865406
[TBL] [Abstract][Full Text] [Related]
25. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice.
Soto-Montenegro ML; Peña-Zalbidea S; Mateos-Pérez JM; Oteo M; Romero E; Morcillo MÁ; Desco M
PLoS One; 2014; 9(11):e111624. PubMed ID: 25369268
[TBL] [Abstract][Full Text] [Related]
26. Detection of "Incidentalomas" on Brain and Body
Umana GE; Ferini G; Harikar MM; Venkataram T; Costanzo R; Scalia G; Palmisciano P; Brunasso L; Paolini F; Sciortino A; Maugeri R; Crea A; Barone F; Inserra F; DA Ros V; Cuttone G; Corsale G; Cristaudo C; Cosentino S; Sabini MG; Ippolito M
Anticancer Res; 2022 Dec; 42(12):5867-5873. PubMed ID: 36456146
[TBL] [Abstract][Full Text] [Related]
27. 68Ga-DOTATOC PET/CT Differentiates Meningioma From Dural Metastases.
Unterrainer M; Ruf V; Ilhan H; Vettermann FJ; Cyran CC; Niyazi M; Bartenstein P; Tonn JC; Albert NL
Clin Nucl Med; 2019 May; 44(5):412-413. PubMed ID: 30829858
[TBL] [Abstract][Full Text] [Related]
28. The Use of 68Ga-DOTA-(Tyr3)-Octreotate PET/CT for Improved Target Definition in Radiotherapy Treatment Planning of Meningiomas - A Case Report.
Grzbiela H; Tarnawski R; D'Amico A; Stąpór-Fudzińska M
Curr Radiopharm; 2015; 8(1):45-8. PubMed ID: 25808961
[TBL] [Abstract][Full Text] [Related]
29. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
30. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT.
Kroiss A; Shulkin BL; Uprimny C; Frech A; Gasser RW; Url C; Gautsch K; Madleitner R; Nilica B; Sprinzl GM; Gastl G; Fraedrich G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):33-41. PubMed ID: 25134670
[TBL] [Abstract][Full Text] [Related]
31. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
Henze M; Schuhmacher J; Hipp P; Kowalski J; Becker DW; Doll J; Mäcke HR; Hofmann M; Debus J; Haberkorn U
J Nucl Med; 2001 Jul; 42(7):1053-6. PubMed ID: 11438627
[TBL] [Abstract][Full Text] [Related]
32. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
Flechsig P; Zechmann CM; Schreiweis J; Kratochwil C; Rath D; Schwartz LH; Schlemmer HP; Kauczor HU; Haberkorn U; Giesel FL
Eur J Radiol; 2015 Aug; 84(8):1593-1600. PubMed ID: 25999064
[TBL] [Abstract][Full Text] [Related]
33. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.
Iglseder S; Iglseder A; Beliveau V; Heugenhauser J; Gizewski ER; Kerschbaumer J; Stockhammer G; Uprimny C; Virgolini I; Dudas J; Nevinny-Stickel M; Nowosielski M; Scherfler C
J Neurooncol; 2023 Sep; 164(3):711-720. PubMed ID: 37707754
[TBL] [Abstract][Full Text] [Related]
35. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
Froeling V; Röttgen R; Collettini F; Rothe J; Hamm B; Brenner W; Schreiter N
Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
[TBL] [Abstract][Full Text] [Related]
36. Pearls and Pitfalls in Interpretation of 68Ga-DOTATOC PET Imaging.
Bashir A; Broholm H; Clasen-Linde E; Vestergaard MB; Law I
Clin Nucl Med; 2020 Jun; 45(6):e279-e280. PubMed ID: 32332303
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
38. Improved Detection of Postoperative Residual Meningioma with [
Bashir A; Larsen VA; Ziebell M; Fugleholm K; Law I
Clin Cancer Res; 2021 Apr; 27(8):2216-2225. PubMed ID: 33526423
[TBL] [Abstract][Full Text] [Related]
39. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
40. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
